A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo‐Bermejo, Violeta Serra, Benedetta Pellegrino et al.|EMBO Molecular Medicine|2018Cited by 271